Latest Breaking News On - Antibody radiation conjugates - Page 1 : comparemela.com

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomGlasgow cityBristol meyersNovo nordiskGroup fedwatchRhythm pharmaceuticalsPhathom pharmaceuticalsExchange commissionFederal reserveEuropean bone marrow transplant society meetingMorgan stanleyActinium pharmaceuticals incActinium pharmaceuticalsEli lillyBiotech performanceNasdaq biotechnology index

Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML

Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGlasgow cityHannah choeEuropean bone marrow transplant society meetingProfessor of medicine at ohio state universityPrnewswire actinium pharmaceuticals incOverall survivalAntibody radiation conjugatesComplete remissionAssistant professorOhio state universityAnnual meeting

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients

Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomGlasgow cityAvinash desaiActimaba national cancer instituteExchange commissionEuropean bone marrow transplant societyActinium pharmaceuticals incActinium pharmaceuticalsAntibody radiation conjugatesComplete remissionOvercomes high riskScottish event campusChief medical officerNorth africanAnnual meetingNational cancer institute

Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy

Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved.

United statesAvinash desaiSandesh sethExchange commissionActimaba national cancer instituteActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incInternational blood marrow transplant researchAmerican society for transplantationAntibody radiation conjugatesTexas southwestern medical centerChief medical officerMemorial sloan ketteringB cell acute lymphoblastic leukemiaDiffuse largeb cell lymphomaCellular therapy meetings

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target Raised to $27 00

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) had its price target raised by Cantor Fitzgerald from $26.00 to $27.00 in a report published on Tuesday, The Fly reports. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2023 earnings at ($1.69) EPS. A number of other analysts have also recently issued reports on the company. William Blair […]

New yorkUnited statesWilliam blairCorton capital incActinium pharmaceuticals company profileNews ratings for actinium pharmaceuticals dailyActinium pharmaceuticals incActinium pharmaceuticalsDelphia united states incActinium pharmaceuticals stockMan groupHedge funds weigh in on actinium pharmaceuticalsCantor fitzgeraldGet ratingActinium pharmaceuticalAntibody radiation conjugates